For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
10
views
Article has an altmetric score of 1
31
references
 Top references
cited by
0
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
2 collections
    0
    shares
      1,062
      similar
       All similar

      Call for Papers: Digital Platforms and Artificial Intelligence in Dementia

      Submit here by August 31, 2025

      About Dementia and Geriatric Cognitive Disorders: 2.2 Impact Factor I 4.7 CiteScore I 0.809 Scimago Journal & Country Rank (SJR)

      Call for Papers: Cancer Biology and Therapy

      Submit here by August 31, 2025

      About Cytogenetic and Genome Research: 1.7 Impact Factor I 3.1 CiteScore I 0.385 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Pembrolizumab-Induced Rhabdomyolysis in a Clear Cell Renal Cell Carcinoma Patient: A Case Report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pembrolizumab is one of the approved treatments for many types of cancer including clear cell renal cell carcinoma (ccRCC). It has improved the prognosis of renal cell carcinoma, yet has many possible immune-related side effects. We discuss a rare case of rhabdomyolysis in an ccRCC patient treated with pembrolizumab. The case was complicated with acute kidney injury and severe hypothyroidism, which can be attributed to pembrolizumab.

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

          James Larkin, Vanna Chiarion-Sileni, Rene Gonzalez … (2015)
          New England Journal of Medicine, 373(1), 23-34
          Article 0 comments Cited 1762 times – based on 0 reviews     Review now
          Article has an altmetric score of 535
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

            Julie Brahmer, Christina Lacchetti, Bryan J Schneider … (2018)
            Purpose To increase awareness, outline strategies, and offer guidance on the recommended management of immune-related adverse events in patients treated with immune checkpoint inhibitor (ICPi) therapy. Methods A multidisciplinary, multi-organizational panel of experts in medical oncology, dermatology, gastroenterology, rheumatology, pulmonology, endocrinology, urology, neurology, hematology, emergency medicine, nursing, trialist, and advocacy was convened to develop the clinical practice guideline. Guideline development involved a systematic review of the literature and an informal consensus process. The systematic review focused on guidelines, systematic reviews and meta-analyses, randomized controlled trials, and case series published from 2000 through 2017. Results The systematic review identified 204 eligible publications. Much of the evidence consisted of systematic reviews of observational data, consensus guidelines, case series, and case reports. Due to the paucity of high-quality evidence on management of immune-related adverse events, recommendations are based on expert consensus. Recommendations Recommendations for specific organ system-based toxicity diagnosis and management are presented. While management varies according to organ system affected, in general, ICPi therapy should be continued with close monitoring for grade 1 toxicities, with the exception of some neurologic, hematologic, and cardiac toxicities. ICPi therapy may be suspended for most grade 2 toxicities, with consideration of resuming when symptoms revert to grade 1 or less. Corticosteroids may be administered. Grade 3 toxicities generally warrant suspension of ICPis and the initiation of high-dose corticosteroids (prednisone 1 to 2 mg/kg/d or methylprednisolone 1 to 2 mg/kg/d). Corticosteroids should be tapered over the course of at least 4 to 6 weeks. Some refractory cases may require infliximab or other immunosuppressive therapy. In general, permanent discontinuation of ICPis is recommended with grade 4 toxicities, with the exception of endocrinopathies that have been controlled by hormone replacement. Additional information is available at www.asco.org/supportive-care-guidelines and www.asco.org/guidelineswiki .
            Article 0 comments Cited 1197 times – based on 0 reviews     Review now
            Article has an altmetric score of 765
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found
              Is Open Access

              Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

              J.B.A.G. Haanen, F Carbonnel, C. Robert … (2017)
              Article 0 comments Cited 645 times – based on 0 reviews     Review now
              Article has an altmetric score of 263
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (nlm-ta): Case Rep Oncol
                Journal ID (iso-abbrev): Case Rep Oncol
                Journal ID (hwp): CRO
                Journal ID (publisher-id): CRO
                Title: Case Reports in Oncology
                Publisher: S. Karger AG (Basel, Switzerland )
                ISSN (Electronic): 1662-6575
                Publication date (Electronic): 25 August 2023
                Publication date Collection: Jan-Dec 2023
                Publication date PMC-release: 25 August 2023
                Volume: 16
                Issue: 1
                Pages: 728-733
                Affiliations
                [a ]Internal Medicine, Hamad Medical Corporation, Doha, Qatar
                [b ]Community Medicine, Hamad Medical Corporation, Doha, Qatar
                [c ]Hamad Medical Corporation, Doha, Qatar
                [d ]Pharmacy Department, National Center for Cancer Care and Research, Hamad Medical Corporation, Doha, Qatar
                [e ]PhD. Candidate, Health Sciences Program, Clinical and Population Health Research, College of Pharmacy, Qatar University, Doha, Qatar
                Author notes
                Correspondence to: Khaled Ali, kali15@ 123456hamad.qa
                Article
                Publisher ID: 532100
                DOI: 10.1159/000532100
                PMC ID: 10601742
                PubMed ID: 37900826
                SO-VID: 9da879f4-b067-4196-88a8-8750b99d9ebf
                Copyright © © 2023 The Author(s). Published by S. Karger AG, Basel
                License:

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                Date received : 20 March 2023
                Date accepted : 11 July 2023
                Date: 2023
                Page count
                Figures: 1, Tables: 1, References: 31, Pages: 6
                Funding
                This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
                Categories
                Subject: Case Report

                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: pembrolizumab,rhabdomyolysis,renal cell carcinoma,oncology
                Data availability:
                ScienceOpen disciplines: Oncology & Radiotherapy
                Keywords: pembrolizumab, rhabdomyolysis, renal cell carcinoma, oncology

                Comments

                Comment on this article

                scite_
                0
                0
                0
                0
                Smart Citations
                0
                0
                0
                0
                Citing PublicationsSupportingMentioningContrasting
                View Citations

                See how this article has been cited at scite.ai

                scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

                Similar content1,062

                See all similar

                Most referenced authors671

                See all reference authors